Enlivex Therapeutics Ltd
ENLV0.835USD
+0.003+0.40%
收盤 12/19, 16:00（美東）報價延遲15分鐘
20.28M總市值
虧損本益比TTM
關於 Enlivex Therapeutics Ltd 公司
Enlivex Therapeutics Ltd is an Israel-based clinical stage macrophage reprogramming immunotherapy company developing Allocetra, off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. AllocetraTM is a therapy designed to reprogram macrophages into their homeostatic state. Diseases such as solid cancers, sepsis, COVID-19 and many others reprogram macrophages out of their homeostatic state. These non-homeostatic macrophages contribute significantly to the severity of the respective diseases. By restoring macrophage homeostasis, AllocetraTM has the potential to provide immunotherapeutic mechanism of action for life-threatening clinical indications that are defined as unmet medical needs, as a stand-alone therapy or in combination with therapeutic agents.
Enlivex Therapeutics Ltd簡介
公司代碼ENLV
公司名稱Enlivex Therapeutics Ltd
上市日期Jul 30, 2014
CEOHershkovitz (Oren)
員工數量36
證券類型Ordinary Share
年結日Jul 30
公司地址14 Einstein St.
城市NESS-ZIONA
上市交易所NASDAQ OMX - NASDAQ BASIC
國家Israel
郵編7403618
電話97286623301
網址https://www.enlivex.com/
公司代碼ENLV
上市日期Jul 30, 2014
CEOHershkovitz (Oren)
Enlivex Therapeutics Ltd公司高管
名稱
名稱/職務
職務
持股
持股變動
Mr. Shai A. Novik
Mr. Shai A. Novik
Executive Chairman of the Board
Executive Chairman of the Board
858.77K
+10.95%
Prof. Dror Mevorach, M.D.
Prof. Dror Mevorach, M.D.
Founder, Chief Scientific Officer and Medical Officer
Founder, Chief Scientific Officer and Medical Officer
242.34K
+3.28%
Dr. Abraham (Avri) Havron, Ph.D.
Dr. Abraham (Avri) Havron, Ph.D.
Independent Director
Independent Director
181.46K
+1.07%
Mrs. Shachar Shlosberger, CPA
Mrs. Shachar Shlosberger, CPA
Chief Financial Officer
Chief Financial Officer
6.41K
+241.84%
Dr. Gili Hart, Ph.D.
Dr. Gili Hart, Ph.D.
Independent Director
Independent Director
5.29K
+56.84%
Dr. Brian Schwartz, M.D.
Dr. Brian Schwartz, M.D.
Director
Director
1.83K
+100.00%
Mr. Matteo Renzi
Mr. Matteo Renzi
Director
Director
--
--
Mr. Sangwoo Lee
Mr. Sangwoo Lee
Director
Director
--
--
Dr. Bernhard Jurgen Kirschbaum, Ph.D.
Dr. Bernhard Jurgen Kirschbaum, Ph.D.
Director
Director
--
--
Dr. Oren Hershkovitz, Ph.D.
Dr. Oren Hershkovitz, Ph.D.
Chief Executive Officer
Chief Executive Officer
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Mr. Shai A. Novik
Mr. Shai A. Novik
Executive Chairman of the Board
Executive Chairman of the Board
858.77K
+10.95%
Prof. Dror Mevorach, M.D.
Prof. Dror Mevorach, M.D.
Founder, Chief Scientific Officer and Medical Officer
Founder, Chief Scientific Officer and Medical Officer
242.34K
+3.28%
Dr. Abraham (Avri) Havron, Ph.D.
Dr. Abraham (Avri) Havron, Ph.D.
Independent Director
Independent Director
181.46K
+1.07%
Mrs. Shachar Shlosberger, CPA
Mrs. Shachar Shlosberger, CPA
Chief Financial Officer
Chief Financial Officer
6.41K
+241.84%
Dr. Gili Hart, Ph.D.
Dr. Gili Hart, Ph.D.
Independent Director
Independent Director
5.29K
+56.84%
Dr. Brian Schwartz, M.D.
Dr. Brian Schwartz, M.D.
Director
Director
1.83K
+100.00%
收入明細
由於公司未披露，未能獲取相關數據
由於公司未披露，未能獲取相關數據
業務
地區
由於公司未披露，未能獲取相關數據
股東統計
更新時間: 12月4日 週四
更新時間: 12月4日 週四
持股股東
股東類型
持股股東
持股股東
佔比
Novik (Shai A)
0.36%
Citizens Financial Group, Inc.
0.10%
Havron (Abraham)
0.08%
Morgan Stanley Smith Barney LLC
0.07%
Renaissance Technologies LLC
0.07%
其他
99.32%
持股股東
持股股東
佔比
Novik (Shai A)
0.36%
Citizens Financial Group, Inc.
0.10%
Havron (Abraham)
0.08%
Morgan Stanley Smith Barney LLC
0.07%
Renaissance Technologies LLC
0.07%
其他
99.32%
股東類型
持股股東
佔比
Individual Investor
0.47%
Investment Advisor
0.23%
Hedge Fund
0.11%
Venture Capital
0.02%
Research Firm
0.02%
其他
99.15%
機構持股
更新時間: 12月8日 週一
更新時間: 12月8日 週一
報告期間
機構數
持股數
持股佔比
持股變動
2025Q4
42
2.79M
13.33%
--
2025Q3
45
2.83M
13.82%
+229.71K
2025Q2
43
2.60M
14.07%
-610.38K
2025Q1
42
3.21M
15.05%
-376.03K
2024Q4
41
3.45M
11.66%
+845.42K
2024Q3
36
4.03M
17.19%
+480.64K
2024Q2
40
3.56M
10.88%
+1.76M
2024Q1
39
1.80M
11.54%
-369.12K
2023Q4
42
1.66M
11.85%
-69.18K
2023Q3
42
1.73M
12.24%
-44.85K
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Novik (Shai A)
858.77K
3.54%
+84.74K
+10.95%
Mar 31, 2025
Havron (Abraham)
181.46K
0.75%
+1.92K
+1.07%
Mar 31, 2025
Morgan Stanley Smith Barney LLC
219.15K
0.9%
-10.58K
-4.61%
Jun 30, 2025
Renaissance Technologies LLC
168.39K
0.69%
-12.90K
-7.11%
Jun 30, 2025
Hershkovitz (Oren Ph.D.)
42.05K
0.17%
+16.55K
+64.92%
Mar 31, 2025
查看更多
持股ETF
機構名稱
佔比
暫無數據
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
常見問題
Enlivex Therapeutics Ltd的前五大股東是誰？
Enlivex Therapeutics Ltd的前五大股東如下：
Novik (Shai A)持有股份：858.77K佔總股份比例：3.54%。
Havron (Abraham)持有股份：181.46K佔總股份比例：0.75%。
Morgan Stanley Smith Barney LLC持有股份：219.15K佔總股份比例：0.90%。
Renaissance Technologies LLC持有股份：168.39K佔總股份比例：0.69%。
Hershkovitz (Oren Ph.D.)持有股份：42.05K佔總股份比例：0.17%。
Novik (Shai A)持有股份：858.77K佔總股份比例：3.54%。
Havron (Abraham)持有股份：181.46K佔總股份比例：0.75%。
Morgan Stanley Smith Barney LLC持有股份：219.15K佔總股份比例：0.90%。
Renaissance Technologies LLC持有股份：168.39K佔總股份比例：0.69%。
Hershkovitz (Oren Ph.D.)持有股份：42.05K佔總股份比例：0.17%。
Enlivex Therapeutics Ltd的前三大股東類型是什麼？
Enlivex Therapeutics Ltd 的前三大股東類型分別是：
Novik (Shai A)
Citizens Financial Group, Inc.
Havron (Abraham)
Novik (Shai A)
Citizens Financial Group, Inc.
Havron (Abraham)
有多少機構持有Enlivex Therapeutics Ltd(ENLV)的股份？
截至2025Q4，共有42家機構持有Enlivex Therapeutics Ltd的股份，合計持有的股份價值約為2.79M，占公司總股份的13.33% 。與2025Q3相比，機構持股有所增加，增幅為-0.48%。
哪個業務部門對Enlivex Therapeutics Ltd的收入貢獻最大？
在--，--業務部門對Enlivex Therapeutics Ltd的收入貢獻最大，創收--，占總收入的--% 。
